These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30167757)

  • 1. Voriconazole greatly increases the exposure to oral buprenorphine.
    Fihlman M; Hemmilä T; Hagelberg NM; Backman JT; Laitila J; Laine K; Neuvonen PJ; Olkkola KT; Saari TI
    Eur J Clin Pharmacol; 2018 Dec; 74(12):1615-1622. PubMed ID: 30167757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction.
    Fihlman M; Hemmilä T; Hagelberg NM; Kuusniemi K; Backman JT; Laitila J; Laine K; Neuvonen PJ; Olkkola KT; Saari TI
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1363-1371. PubMed ID: 27510521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
    Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
    Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voriconazole drastically increases exposure to oral oxycodone.
    Hagelberg NM; Nieminen TH; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
    Eur J Clin Pharmacol; 2009 Mar; 65(3):263-71. PubMed ID: 18836708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers.
    Bai SA; Xiang Q; Finn A
    Clin Ther; 2016 Feb; 38(2):358-69. PubMed ID: 26804639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome.
    van Hoogdalem MW; Johnson TN; McPhail BT; Kamatkar S; Wexelblatt SL; Ward LP; Christians U; Akinbi HT; Vinks AA; Mizuno T
    Clin Pharmacol Ther; 2022 Feb; 111(2):496-508. PubMed ID: 34679189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
    Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
    Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl.
    Saari TI; Laine K; Neuvonen M; Neuvonen PJ; Olkkola KT
    Eur J Clin Pharmacol; 2008 Jan; 64(1):25-30. PubMed ID: 17987285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voriconazole and fluconazole increase the exposure to oral diazepam.
    Saari TI; Laine K; Bertilsson L; Neuvonen PJ; Olkkola KT
    Eur J Clin Pharmacol; 2007 Oct; 63(10):941-9. PubMed ID: 17676319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.
    Moody DE; Liu F; Fang WB
    J Anal Toxicol; 2015 Jun; 39(5):374-86. PubMed ID: 25868557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole.
    Kivistö KT; Lamberg TS; Kantola T; Neuvonen PJ
    Clin Pharmacol Ther; 1997 Sep; 62(3):348-54. PubMed ID: 9333111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of voriconazole on the pharmacokinetics of diclofenac.
    Hynninen VV; Olkkola KT; Leino K; Lundgren S; Neuvonen PJ; Rane A; Valtonen M; Laine K
    Fundam Clin Pharmacol; 2007 Dec; 21(6):651-6. PubMed ID: 18034666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal system.
    Kapil RP; Cipriano A; Michels GH; Perrino P; O'Keefe SA; Shet MS; Colucci SV; Noveck RJ; Harris SC
    Clin Drug Investig; 2012 Sep; 32(9):583-92. PubMed ID: 22845044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine.
    Grün B; Merkel U; Riedel KD; Weiss J; Mikus G
    Br J Clin Pharmacol; 2012 Nov; 74(5):854-63. PubMed ID: 22381043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers.
    Liukas A; Hagelberg NM; Kuusniemi K; Neuvonen PJ; Olkkola KT
    J Clin Psychopharmacol; 2011 Jun; 31(3):302-8. PubMed ID: 21508859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects.
    Hagelberg NM; Fihlman M; Hemmilä T; Backman JT; Laitila J; Neuvonen PJ; Laine K; Olkkola KT; Saari TI
    Pharmacol Res Perspect; 2016 Dec; 4(6):e00271. PubMed ID: 28097004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Drug-Drug Interaction Liability for Buprenorphine Extended-Release Monthly Injection Administered by Subcutaneous Route.
    Kharidia J; Howgate EM; Laffont CM; Liu Y; Young MA
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1064-1074. PubMed ID: 33750027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine.
    Kuhlman JJ; Lalani S; Magluilo J; Levine B; Darwin WD
    J Anal Toxicol; 1996 Oct; 20(6):369-78. PubMed ID: 8889672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Itraconazole increases plasma concentrations of quinidine.
    Kaukonen KM; Olkkola KT; Neuvonen PJ
    Clin Pharmacol Ther; 1997 Nov; 62(5):510-7. PubMed ID: 9390107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen.
    Hynninen VV; Olkkola KT; Leino K; Lundgren S; Neuvonen PJ; Rane A; Valtonen M; Vyyryläinen H; Laine K
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1967-72. PubMed ID: 16723553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.